Bernie Sanders demands to know why leukemia drug costs $200,000 a year – leading to fall in stock price
Sanders sent a letter to the company co-signed by Representative Elijah Cummings
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Former Democratic presidential candidate Bernie Sanders and U.S. Representative Elijah Cummings issued a letter on Thursday seeking information from Ariad Pharmaceuticals Inc on the “staggering” price increases for the company's leukemia drug.
Ariad's shares reversed course to trade down 6 percent at $10.17 after rising more than 4 percent earlier on Thursday.
The letter was sent a week after Sanders tweeted that: “Drug corporations' greed is unbelievable. Ariad raised the price of a leukemia drug to almost $199,000 a year.”
Ariad's drug, Iclusig, was approved in December 2012 and is used to treat chronic myeloid leukemia, a type of bone marrow cancer in which marrow makes too many white blood cells.
Iclusig generated sales of $65.3 million in the second quarter.
The company's pricing strategy came under scrutiny after the TheStreet reported earlier this month that the company had raised the price of the drug. (bit.ly/2dcBAmg)
“In the interest of patients and taxpayers, we are interested in learning more about the impact that the escalating price and restrictions on product availability have had,” Sanders and Cummings, a Maryland Democrat, said in the letter.
Ariad did not immediately respond to request for comment.
Criticism of Ariad, led by Chief Executive Paris Panayiotopoulos, comes at a time when Mylan NV is being lambasted by consumers and lawmakers for raising prices on its lifesaving EpiPen six-fold to over $600 for a package of two in less than a decade.
Mylan said earlier this month it would pay $465 million to settle questions over whether it underpaid U.S. government healthcare programs by misclassifying the EpiPen anti-allergy drug delivery device.
Aggressive drug pricing has come under intense scrutiny after Democratic Presidential candidate Hillary Clinton tweeted her intent to tackle high prices last year.
Clinton's tweets have hit shares of Mylan and Valeant Pharmaceuticals International, whose pricing strategy has been investigated by U.S. regulators and lawmakers.
Drug companies are already responding to political pressure. Botox maker Allergan Plc recently committed to keeping price increases below 10 percent.